Science Hub is Novo Nordisk’s one-stop portal for all our scientific publications and clinical trials, congress materials and medical updates. Sign up to gain full access.
Efficacy and safety of co-administered cagrilintide-semaglutide (CagriSema) 1.7 mg each and 1.0 mg each in adults with overweight or obesity (REDEFINE 9): a multicentre, randomised, double-blind within-dose-level, placebo-controlled, parallel-group, phase 3b trial
Sorry! It looks like the page you are trying to access contains materials that are still under embargo. Please come back and check again later.